Sun Pharma offers $3.2bn for ailing Ranbaxy

Sun Pharmaceutical Industries of India is to pay $3.2bn for the equity in Ranbaxy, the Indian generic drug maker that has suffered a string of US import bans

Leave a Reply

Your email address will not be published. Required fields are marked *